hOGG1 Ser326Cys polymorphism and susceptibility to gallbladder cancer in a Chinese population

• Published in: International journal of cancer Vol. 121; no. 3; pp. 501 - 505
• Main Authors: Jiao, Xingyuan, Huang, Jiefu, Wu, Shengli, MingdeLv, Hu, Yize, Jianfu, Su, Xiaokang, Luo, Canqiao, Broelsch, CE
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01-08-2007; Wiley-Liss
• Subjects: Asian Continental Ancestry Group - genetics; Biological and medical sciences; Case-Control Studies; China; Cysteine; DNA Glycosylases - genetics; Female; gallbladder cancer; Gallbladder Neoplasms - genetics; Gastroenterology. Liver. Pancreas. Abdomen; Gene Frequency; Genetic Predisposition to Disease; hOGG1; Humans; Liver. Biliary tract. Portal circulation. Exocrine pancreas; Male; Medical sciences; Middle Aged; polymorphism; Polymorphism, Genetic; Serine; susceptibility; Tumors; Asia; China; Human; Genetic variability; susceptibility; Biliary tract cancer; Genotype; Malignant tumor; Biliary tract disease; Gallbladder cancer; Gall bladder cancer; Cancerology; China; Digestive diseases; Chinese; hOGGI; Polymorphism
• ISSN: 0020-7136; 1097-0215
• DOI: 10.1002/ijc.22748

The human oxoguanine glycosylase 1(hOGG1) gene encodes a DNA glycosylase that is involved in excision repair of 8‐OH‐dG (8‐hydroxy‐2‐deoxyguanine) from oxidatively‐damaged DNA. To determine whether hOGG1 plays a role in the risk for adenocarcinoma of the gallbladder, we tested the association of this polymorphism with gallbladder cancer in a Chinese population‐based, case control study of 204 cases and 209 controls. The subjects were genotyped with a polymerase chain reaction‐restriction fragment length polymorphism (PCR–RELP) assay. The association between the genetic polymorphism of this gene and risk of the cancer was examined by using a multivariate analysis. We found that the distribution of hOGG1 Ser326Cys genotypes among controls (Ser/Ser, 37.3%; Ser/Cys, 53.6% and Cys/Cys, 9.1%) was significantly different from that among gallbladder cancer cases (Ser/Ser, 43.1%; Ser/Cys, 36.3% and Cys/Cys, 20.6%). Significantly increased risk for gallbladder cancer was both the hOGG1 326Ser/Cys (Odds ratio [OR] = 1.9, 95% confidence interval (CI) = 1.0–3.7) and hOGG1 326Cys/Cys genotypes (OR = 4.5, 95% CI = 1.1–22.4). We observed no statistically significant association between hOGG1 genotype and gallbladder cancer association in gallstone absence. In contrast, a near‐significant increase in risk for gallbladder cancer was observed for gallstone presence with the hOGG1 326Ser/Cys genotype (OR = 2.2, CI = 1.4–3.5) whereas a significant increase in association for gallbladder cancer was observed for gallstone presence with the 326Cys/Cys genotype (OR = 6.1, CI = 2.1–27.2). These data corresponded with the fact that a significant trend towards increased association for gallbladder cancer was observed with potentially higher‐risk hOGG1 genotypes in gallstone presence(p < 0.001, χ2 trend test)but not in gallstone absence(p = 0.89, χ2 trend test). A significant increase in risk for gallbladder cancer was observed for larger gallstone (those with stone diameters 2 cm or greater) with the hOGG1 326Ser/Cys(OR = 1.9, 95% CI = 1.1–2.9) and hOGG1 326Cys/Cys genotypes(OR = 5.9, 95% CI = 1.6–18.0). These data are consistent with the observation that a significant trend towards increased risk for gallbladder cancer was observed with potentially higher‐risk hOGG1 genotypes in gallbladder cancer patients with larger gallstone (p < 0.001, χ2 trend test). However, we observed no statistically significant association between hOGG1 genotype and gallbladder cancer risk in gallbladder cancer patients with smaller gallstone (those with stone diameters 2 cm smaller) (hOGG1 326Ser/Cys:OR = 2.2, 95% CI = 0.8–4.0; hOGG1 326Cys/Cys:OR = 2.9, 95% CI = 0.6–29.4; p = 0.06, χ2 tread test). These results suggest that hOGG1 Ser326Cys polymorphism is associated with gallbladder cancer risk. © 2007 Wiley‐Liss, Inc.